Upgrade to SI Premium - Free Trial

Moleculin Biotech (MBRX)

0.71 +0.03 (4.41%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/9/26)

Latest Headlines

Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference August 27, 2026 9:01 AM - StreetInsider Form SCHEDULE 13D Moleculin Biotech, Inc. Filed by: Foster Jonathan P. August 25, 2026 4:24 PM - SEC Filing Form SCHEDULE 13D Moleculin Biotech, Inc. Filed by: KLEMP WALTER V August 25, 2026 4:23 PM - SEC Filing Form DEFA14A Moleculin Biotech, Inc. August 24, 2026 5:11 PM - SEC Filing Form DEF 14A Moleculin Biotech, Inc. For: Oct 09 August 24, 2026 5:01 PM - SEC Filing Form 424B5 Moleculin Biotech, Inc. August 21, 2026 5:16 PM - SEC Filing Form PRE 14A Moleculin Biotech, Inc. For: Oct 09 August 14, 2026 5:07 PM - SEC Filing Form 8-K Moleculin Biotech, Inc. For: Aug 14 August 14, 2026 8:31 AM - SEC Filing Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial August 14, 2026 8:30 AM - StreetInsider Form 10-Q Moleculin Biotech, Inc. For: Jun 30 August 13, 2026 4:18 PM - SEC Filing Form SCHEDULE 13G Moleculin Biotech, Inc. Filed by: CVI Investments, Inc. August 10, 2026 6:38 PM - SEC Filing Form SCHEDULE 13G Moleculin Biotech, Inc. Filed by: INTRACOASTAL CAPITAL, LLC August 6, 2026 5:27 PM - SEC Filing Form 4 Moleculin Biotech, Inc. For: Aug 03 Filed by: Foster Jonathan P. August 5, 2026 4:21 PM - SEC Filing Form 4 Moleculin Biotech, Inc. For: Aug 03 Filed by: KLEMP WALTER V August 5, 2026 4:20 PM - SEC Filing Form 4 Moleculin Biotech, Inc. For: Aug 03 Filed by: PICKER DONALD H August 5, 2026 4:19 PM - SEC Filing Form 8-K Moleculin Biotech, Inc. For: Jul 31 August 3, 2026 5:12 PM - SEC Filing Form 424B5 Moleculin Biotech, Inc. August 3, 2026 9:48 AM - SEC Filing Form EFFECT Moleculin Biotech, Inc. August 3, 2026 6:08 AM - SEC Filing Moleculin prices $9.3M public offering at $0.75 per share July 31, 2026 10:12 AM - StreetInsider Moleculin Announces Pricing of $9.3 Million Public Offering  July 31, 2026 10:12 AM - StreetInsider Moleculin reports 37% blinded remission rate in AML trial interim data July 31, 2026 8:10 AM - StreetInsider Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients July 31, 2026 8:10 AM - StreetInsider Form 8-K Moleculin Biotech, Inc. For: Jul 31 July 31, 2026 8:00 AM - SEC Filing Form S-1/A Moleculin Biotech, Inc. July 31, 2026 6:04 AM - SEC Filing Form S-1/A Moleculin Biotech, Inc. July 30, 2026 5:06 PM - SEC Filing Form S-1 Moleculin Biotech, Inc. July 29, 2026 9:41 AM - SEC Filing Moleculin CEO discusses early MIRACLE trial data in investor segment July 6, 2026 8:33 AM - StreetInsider Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment July 6, 2026 8:33 AM - Globe NewsWire Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment July 6, 2026 8:33 AM - StreetInsider Form 8-K Moleculin Biotech, Inc. For: Jun 30 June 30, 2026 8:30 AM - SEC Filing Form 8-K Moleculin Biotech, Inc. For: Jun 30 June 30, 2026 8:30 AM - SEC Filing Moleculin reports interim AML trial data showing higher remission rates June 30, 2026 8:30 AM - StreetInsider Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control June 30, 2026 8:30 AM - StreetInsider Form 4 Moleculin Biotech, Inc. For: Jun 20 Filed by: PICKER DONALD H June 24, 2026 9:01 PM - SEC Filing Form 4 Moleculin Biotech, Inc. For: Jun 20 Filed by: KLEMP WALTER V June 24, 2026 9:01 PM - SEC Filing Form 4 Moleculin Biotech, Inc. For: Jun 20 Filed by: Foster Jonathan P. June 24, 2026 9:00 PM - SEC Filing Full Article List